急性缺血性卒中脑保护:展望未来
本文反思缺血性卒中治疗转化失败的原因,指出既往单靶点神经保护剂研发因临床前与临床研究严谨性不足而受挫。作者建议以「脑细胞保护」替代「神经保护」概念,强调神经血管单元差异易损性,并倡导多靶点药物及更严格的临床前评估。
要点
- 单靶点神经保护剂转化失败,需转向多靶点或多效性治疗策略。
- 「神经保护」概念应改为「脑细胞保护」,涵盖整个神经血管单元。
- 临床前评估应纳入老龄、双性别及合并症动物模型,并强化严谨性。
核心结论
- 单靶点神经保护剂研发失败,未来应聚焦多靶点脑细胞保护策略并强化科研严谨性。
研究设计与样本
- 本文为综述性文章,总结既往缺血性卒中治疗开发失败教训并提出新方向,未报告系统检索范围。
主要发现
- 既往候选治疗的临床前评估常缺乏严谨性和充分性,临床试验可能缺乏效力、严谨性或正确性。
- 针对特定分子机制的单靶点药物被证明不成功。
- 多效性多靶点药物(如治疗性低温、3K3A-APC)或单靶点药物NA-1触发多条下游信号事件可能更有前景。
临床怎么用
- 临床前研究应选择适合研究目的动物模型,并纳入老龄、双性别及合并糖尿病或高血压等合并症受试者。
- 脑保护治疗可作为血管再通的辅助治疗或独立治疗。
- 资助机构和期刊可强制执行临床前科学严谨性原则。
局限性
- 本文未报告系统检索策略,结论基于叙述性总结。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We search for ischemic stroke treatment knowing we have failed-intensely and often-to translate mechanistic knowledge into treatments that alleviate our patients' functional impairments. Lessons can be derived from our shared failures that may point to new directions and new strategies. First, the principle criticisms of both preclinical and clinical assessments are summarized. Next, previous efforts to develop single-mechanism treatments are reviewed. Finally, new definitions, novel approaches, and different directions are presented. In previous development efforts, the basic science and preclinical assessment of candidate treatments often lacked rigor and sufficiency; the clinical trials may have lacked power, rigor, or rectitude; or most likely both preclinical and clinical investigations were flawed. Single-target agents directed against specific molecular mechanisms proved unsuccessful. The term neuroprotection should be replaced as it has become ambiguous: protection of the entire neurovascular unit may be called cerebral cytoprotection or cerebroprotection. Success in developing cerebroprotection-either as an adjunct to recanalization or as stand-alone treatment-will require new definitions that recognize the importance of differential vulnerability in the neurovascular unit. Recent focus on pleiotropic multi-target agents that act via multiple mechanisms of action to interrupt ischemia at multiple steps may be more fruitful. Examples of pleiotropic treatments include therapeutic hypothermia and 3K3A-APC (activated protein C). Alternatively, the single-target drug NA-1 triggers multiple downstream signaling events. Renewed commitment to scientific rigor is essential, and funding agencies and journals may enforce quality principles of rigor in preclinical science. Appropriate animal models should be selected that are suited to the purpose of the investigation. Before clinical trials, preclinical assessment could include subjects that are aged, of both sexes, and harbor comorbid conditions such as diabetes or hypertension. With these new definitions, novel approaches, and renewed attention to rigor, the prospect for successful cerebroprotective therapy should improve.
引用
- Lyden PD. Cerebroprotection for Acute Ischemic Stroke: Looking Ahead. Stroke. 2021. PMID: 34289710. doi:10.1161/STROKEAHA.121.032241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。